Veracyte Inc (VCYT)

Debt-to-capital ratio

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Long-term debt US$ in thousands — — — — — — — — — — — — — — — — — — — —
Total stockholders’ equity US$ in thousands 1,221,060 1,194,940 1,175,970 1,176,040 1,132,520 1,118,650 1,044,100 1,054,060 1,082,720 1,081,260 1,075,200 1,048,180 1,064,150 1,085,190 1,096,510 1,107,080 971,177 974,231 421,232 422,725
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

June 30, 2025 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1,221,060K)
= 0.00

The analysis of Veracyte Inc's debt-to-capital ratio across the reported periods reveals a consistent value of zero from September 30, 2020, through June 30, 2025. This indicates that the company has not employed debt financing as a component of its capital structure during this timeframe. Such a stable and zero debt-to-capital ratio suggests that Veracyte Inc's capital has been entirely financed through equity or other non-debt sources. The absence of debt implies a low financial leverage, which reduces financial risk associated with interest obligations but may also limit financial flexibility or leverage benefits. Overall, the data reflects a predominantly equity-backed or internally financed capital structure with no reliance on external debt instruments for funding.